Monthly Archives: September 2013

Galax-C – ”Medicine Cabinet” (Prod. Chris Calor) *NEW* *SEPTEMBER* 720p – Video

Posted on by


Galax-C - #39; #39;Medicine Cabinet #39; #39; (Prod. Chris Calor) *NEW* *SEPTEMBER* 720p
What was going to be the Intro for the highly anticipated mixtape One 800 comes out sometime in October for futher notice make sure to follow us on Twitter,I...

By: Guich Boyz

Go here to read the rest:

Galax-C - ''Medicine Cabinet'' (Prod. Chris Calor) *NEW* *SEPTEMBER* 720p - Video

Daniel Bryan WINS – The Shield Gets a Taste of Their Own Medicine – YES! – Reaction by JDV – Video

Posted on by


Daniel Bryan WINS - The Shield Gets a Taste of Their Own Medicine - YES! - Reaction by JDV
YES! Daniel Bryan wins, pinning Seth Rollins and defeating The Shield in a huge tag match with the many WWE Superstars supporting Daniel Bryan in a tag match...

By: Conservative New Media

See original here:

Daniel Bryan WINS - The Shield Gets a Taste of Their Own Medicine - YES! - Reaction by JDV - Video

Nuclear Medicine Market & Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation …

Posted on by

NEW YORK, Sept. 26, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Nuclear Medicine Market & Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to 2017 http://www.reportlinker.com/p01650887/Nuclear-Medicine-Market--Radiopharmaceuticals-%5BSPECT/PET-Radioisotopes-Technetium-F-18%5D-%5BBeta/Alpha-radiation-therapy-I131-Y-90%5D-%5BApplications-Cancer/Oncology-Cardiac%5D--Stable-Isotopes-Deuterium-C-13---Global-Trends--Forecast-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging

Nuclear Medicine Market & Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to 2017

The global radiopharmaceuticals market was valued at $3.8 billion in 2012 and is poised to reach $5.5 billion by 2017 at a CAGR of 7.8%.

A study conducted by Organization for Economic Co-operation and Development (OECD) estimates that Tc-99m diagnostic procedures are expected to increase by 15% to 20% in mature markets such as Europe, North America, Japan, the Republic of Korea, and Oceania between 2010 and 2030. Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are also being preferred by practitioners besides conventional treatment. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The scheduled shutdown of the NRU reactor in 2016 and OSIRIS in France in 2018 is, however, a major threat for manufacturers.

The therapy market is predominantly driven by its oncologic applications. Since conventional treatment procedures of cancer, surgery and chemotherapy have significant side effects, radioisotopes are being preferred by medical practitioners due to minimum or no side effects. The radiopharmaceutical therapy market is expected to grow significantly with the launch of the much-desired Alpharadin (Ra-223) in the near future. This isotope has tremendous potential to take up market share of beta emitters and brachytherapy.

North America is the dominant market for diagnostic radioisotopes with 49% share. The U.S. is the largest consumer market for radiopharmaceuticals in North America, while Canada is one of the largest producers of Tc-99m. Major players in the radiopharmaceuticals market are Cardinal Health, Inc. (U.S.), Covidien, Plc (Ireland), GE Healthcare (U.K.), IBA Group (Belgium), Lantheus Medical Imaging, Inc. (U.S.), Nordion, Inc. (Canada), and Siemens Healthcare (PETNET) (Germany).

The stable isotopes market was led by two players - Cambridge Isotope Laboratories (CIL) (U.S.) and Isotec (Sigma Aldrich) (U.S.) - in 2012; they jointly contributed more than 90% to the global revenue.

Scope of the Report

The radioisotope and stable isotope markets have been segmented according to the type of isotope, and applications. Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by geography (North America, Europe, Asia, and Rest of the World) to provide in-depth information on the global scenario.

View original post here:

Nuclear Medicine Market & Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation ...

Penn Medicine's Garret FitzGerald Named Ohio State Heart Program 2013 Schottenstein Laureate

Posted on by

Newswise PHILADELPHIA - Garret FitzGerald, MD, FRS, professor of Medicine and Pharmacology; chair of the Department of Pharmacology; and director of the Institute for Translational Medicine and Therapeutics at the Perelman School of Medicine, University of Pennsylvania is the 2013 recipient of the Jay and Jeanine Schottenstein Prize in Cardiovascular Sciences from The Ohio State University Wexner Medical Centers Heart and Vascular Center.

The Schottenstein Prize, established with a $2 million gift from philanthropists Jay and Jeanie Schottenstein, is awarded to an international leader in the clinical sciences of cardiovascular medicine, cardiothoracic surgery, or the basic sciences of molecular or cellular cardiology. With the gift, the Schottenstein Laureate receives an honorarium of at least $100,000. FitzGerald will receive the award, one of the largest in the field, during a ceremony in Columbus on Oct 2.

I am honored to receive this prize, which reflects on the dedication and hard work of so many people with whom Ive been privileged to work and collaborate, says FitzGerald.

His research takes an integrative approach to elucidating the mechanisms of drug action, drawing on work in cells, model organisms, and humans. His work contributed substantially to the development of low-dose aspirin for cardioprotection. His team discovered how lower doses of aspirin than had been previously used to treat pain and inflammation act on blood cells called platelets to shut down their role in blocking arteries to cause heart attacks and strokes. Low-dose aspirin is now used for this purpose throughout the world and has saved the lives of tens of millions of people. His group was also the first to predict and then mechanistically explain the cardiovascular hazard from nonsteroidal antinflammatory drugs - NSAIDs. Between his work on aspirin and NSAIDs, he has benefited ten, if not hundreds, of millions of patients worldwide. His laboratory also described the first molecular clock in the cardiovascular system.

While in Columbus, FitzGerald will lecture during a special Grand Rounds in the Richard M. Ross Heart Hospital and meet with cardiovascular researchers at the Dorothy M. Davis Heart and Lung Research Institute.

For more information view the Ohio State release.

### Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 16 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $398 million awarded in the 2012 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2012, Penn Medicine provided $827 million to benefit our community.

Go here to read the rest:

Penn Medicine's Garret FitzGerald Named Ohio State Heart Program 2013 Schottenstein Laureate

Penn Medicine Radiation Oncology Chair Named Among 2013 ASTRO Fellows

Posted on by

ATLANTA Stephen M. Hahn, MD, chairman of the Department of Radiation Oncology and Henry K. Pancost Professor of Radiation Oncology in the Perelman School of Medicine and Abramson Cancer Center at the University of Pennsylvania, has been named among the ten 2013 Fellows of the American Society for Radiation Oncology.

Dr. Hahn became the chair of Penn Medicines Department of Radiation Oncology in 2005, after joining Penns faculty in 1996. During his tenure, he has overseen the opening of the Roberts Proton Therapy Center, the worlds largest and most advanced center integrating both proton beam radiation therapy and conventional radiation.

He received the FASTRO recognition this week during the organizations 55th Annual Meeting at the Georgia World Congress Center in Atlanta.

Awarded annually since 2006, ASTROs Fellows Program honors radiation oncology leaders who have been an ASTRO member for at least 15 years and have made substantial contributions to the field of radiation oncology in the areas of research, education, patient care or service, and leadership. Including the 2013 class of 10 Fellows, 212 of ASTROs more than 10,000 members worldwide have received the FASTRO designation.

Prior to his arrival at Penn, Dr. Hahn served as chief of the National Cancer Institutes Prostate Cancer Clinic, Clinical Pharmacology Branch, in Bethesda, MD, and as senior investigator at the NCI. He also served as a Commander in the NCIs U.S. Public Health Service from 1989 to 1995.

Dr. Hahns research and clinical care concentrates on cancers of the lung and genitourinary system, as well as radiation biology and photodynamic therapy. He is board certified in Internal Medicine, Radiation Oncology, and Hematology/Oncology, and is a graduate of the Temple University School of Medicine and Rice University. He completed his internal medicine residency atthe University of California, San Francisco and received fellowship training in both medical oncology and radiation oncology at the NCI. He has been a longtime member and leader of various ASTRO committees and initiatives.

These 10 new Fellows join an elite group of ASTRO members who have significantly impacted ASTRO, the specialty and cancer patients worldwide through their leadership in and service to research, education and patient care efforts, said ASTRO President Colleen A. F. Lawton, MD, FASTRO. Congratulations to my esteemed colleagues on receiving the ASTRO Fellow designation.

To read more about the 2013 FASTRO awardees, visit the ASTRO web site.

View post:

Penn Medicine Radiation Oncology Chair Named Among 2013 ASTRO Fellows

Medical School Researchers Urge Earlier, More Frequent Mammograms

Posted on by

A study by researchers from Harvard Medical School has found that women should have mammograms performed yearly beginning at age 40, contrary to government recommendations that state the screenings should occur biennially beginning at age 50.

The study, published in the American Cancer Societys Cancer journal on Sept. 9, found that most breast cancer deaths occur in young women who do not receive routine mammogram screening.

Annual screenings started at 40 increased mortality reduction by almost double, said Blake Cady, one of the studys co-authors and a professor emeritus at the Medical School. A 70 percent mortality reduction equals 22 more lives saved per thousand.

The study analyzed data on breast cancer diagnoses at the Partners HealthCare hospitals in Boston between 1990 and 1999 and followed each case through 2007. The studys results showed that 29 percent of women who died from cancer had received prior screening, while the remaining 71 percent had not.

Its a very controversial topic, said Matthew L. Webb 09, the lead author of the study and a researcher at Massachusetts General Hospital. Something like one in eight women in their lifetime will get breast cancer.

The studys recommendation challenges a report from the United States Preventative Services Task Force, or USPSTF, which suggests women get screened for breast cancer every two years between the ages of 50 and 74.

According to Daniel B. Kopans, one of the studys co-authors, the USPSTF made their recommendation in spite of evidence that most lives were saved through screenings beginning at age 40 in order to reduce false-positive test results.

They didnt know the data and came to faulty conclusions, said Kopans, who is also a radiology professor at the Medical School.

Though Susan G. Komen for the Cure, a foundation devoted to breast cancer research, said the risk of false positives among women who receive yearly mammograms could cause long-term psychological harm, Cady said yearly mammograms are still critical.

Paradoxically, if you do mammography every year, the rate of false positive is much less than if you do mammography every two or three years because radiologists can look back a year ago and if they see something consistent, they dont have to call for extra film, Cady said.

Read more:

Medical School Researchers Urge Earlier, More Frequent Mammograms

Proposed medical school in jeopardy

Posted on by

BRISTOL, Va. -

The future of a proposed medical school is in jeopardy after the projects biggest benefactor puts a freeze on funds.

The Virginia Tobacco Commission voted Thursday to suspend payment of $1,000,000 given to the King School of Medicine for development.

"We want to see some progress being made. Three years and we haven't seen some hard evidence that this is actually going to go forward," said commission er Senator Bill Carrico.

$40,000,000 is pledged to the project. An additional $24,000,000 from the Tobacco Commission and $7.5 million from both Washington County, Virginia and the town of Abingdon.

School developers only need to come up with $10 million, but so far have nothing.

"It raises a lot of red flags," said Washington County Supervisor Bill Gibson."I've never been opposed to the King School of Medicine concept, but I am opposed to the tax dollars of Washington county and Abingdon citizens paying the bill."

The school's interim president Tariq Zaidi tells News 5 he's not concerned.

"We believe that as we go into the 4th quarter of this year we will be able to make some significant announcements regarding partnerships and some other goals we've set,"said Zaidi.

Senator Carrico and others say time's up.

See the article here:

Proposed medical school in jeopardy

UCSF First U.S. Medical School to Offer Credit For Wikipedia Articles

Posted on by

UC San Francisco soon will be the first U.S. medical school at which medical students can earn academic credit for editing medical content on Wikipedia.

Wikipedia is one of the most widely used medical references in the world and the most consulted source for many health topics. But medical entries can lack reliable sources and have gaps in content.

Amin Azzam, MD, MA, will be teaching a UCSF course in which students will

contribute and edit medical information on Wikipedia.

Wikipedia generates more than 53 million page views just for articles about medications each month, and is second to Google as the most frequently used source by junior physicians, said Amin Azzam, MD, MA, an associate clinical professor at the UCSF School of Medicine and an instructor for the new class. Were recognizing the impact Wikipedia can have to educate patients and health care providers across the globe, and want users to receive the most accurate publicly available, sound medical information possible.

One of the key skills medical students are expected to acquire is the ability to seek, evaluate and interpret the medical literature for themselves, their peers and their patients. In traditional medical school courses, first and second year students are taught this skill in small group classroom sessions, while third and fourth year students are expected to apply this in the hospital wards and outpatient clinics.

Writing and editing Wikipedia articles requires a similar skill set, and teaches our students how to write for a broader audience and communicate with patients using consumer-friendly language rather than doctor jargon, said Azzam.

Enrolled medical students will edit articles remotely, adding images, reviewing new edits, adding citations to support unreferenced text, and providing a form of peer review. Professors can track the edits and changes made to each Wikipedia page to monitor the evolution of the content.

Read the original here:

UCSF First U.S. Medical School to Offer Credit For Wikipedia Articles

Liberty Mutual Insurance Celebrates The "Rise" Of 13 U.S. Olympic And Paralympic Athletes

Posted on by

BOSTON, Sept. 26, 2013 /PRNewswire/ --Liberty Mutual Insurance, the Official Property and Casualty and Life Insurance Partner of the 2014 and 2016 U.S. Olympic and Paralympic Teams, today unveiled the roster of U.S. Olympic and Paralympic athletes the company will support for the 2014 Olympic and Paralympic Winter Games in Sochi, Russia. Team Liberty Mutual will assist the insurer in their new marketing campaign, which celebrates human persistence, highlights what is possible with the support of others, and showcases the determination in all who face a setback to come back and "Rise."

(Logo: http://photos.prnewswire.com/prnh/20130926/NE86453LOGO )

"Liberty Mutual has been providing support, strength and hope to our customers as they attempt to come back from life's setbacks for more than 100 years and this great team of athletes reminds us that with the right amount of support, every one of us can come back and achieve great things," said Paul G. Alexander, Liberty Mutual Insurance chief communications officer. "These athletes have endured struggles, just like many of our customers, and we are proud to be an ally to them both. We know the dedication it takes to become the best at what you do and are thrilled to support them on their journeys for Olympic gold."

Meet Team Liberty Mutual

Each of the U.S. Olympic and Paralympic hopefuls, athletes and legends selected to Team Liberty Mutual for the Olympic and Paralympic Winter Games reflects the "Rise" theme. Altogether, Team Liberty Mutual members have appeared in a combined 12 Olympic Winter Games, winning eight Olympic and Paralympic medals, as well as numerous national and international titles. Members of Team Liberty Mutual include:

"I am thrilled to team up with Liberty Mutual Insurance and this incredible group of athletes," said short track speedskater J.R. Celski, who won bronze medals in the 1500m and 5000m relay in Vancouver. "I have faced setback and challenges along my journey and I would not be able to succeed at my dream without the support of friends, family and sponsors, like Liberty Mutual Insurance, who help me rise up to reach my goals."

Leading up to and during the Olympic Winter Games, fans can watch a series of moving "Rise" vignettes that follow the inspirational journey of each Team Liberty Mutual athlete at LibertyMutual.com/TeamUSA. In addition to highlighting Liberty Mutual Insurance's "Rise" campaign, these videos are designed to engage Americans in celebrating the power of human persistence as well as rallying support for these inspirational members of Team USA.

An Ongoing Commitment to Team USA and Youth Sports

In addition to announcing their team of athletes, Liberty Mutual Insurance is proud to be the presenting sponsor of the USOC's Road to Sochi Tour. Visitors to Liberty Mutual Insurance's experiential footprint at the Road to Sochi Tour will be able to learn more about the "Rise" campaign and Team Liberty Mutual, meet U.S. Olympians and Paralympians past and present, and participate in the Rise social conversation by thanking someone who helped them rise from a challenge using #RISE. The company is committed to supporting Team USA through multiple other initiatives leading up to and during the Sochi 2014 Olympic Winter Games as well as the 2016 Summer Olympic Games in Rio de Janeiro as the official auto, home, life and business insurance partner of the USOC.

The company also supports the development of youth sports through its Liberty Mutual Insurance Responsible Sports initiative, which provides resources to volunteer youth sports coaches and parents who help children succeed both on and off the field. Since 2007, the Liberty Mutual Insurance Responsible Sports program has supported youth sports organizations across the country through partnerships with Positive Coaching Alliance, Amateur Softball Association of America, USA Hockey, USA Wrestling, US Youth Soccer, USA Volleyball and USA Water Polo.

More here:

Liberty Mutual Insurance Celebrates The "Rise" Of 13 U.S. Olympic And Paralympic Athletes